Last reviewed · How we verify
Clindamycin Phosphate RLD — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Clindamycin Phosphate RLD (Clindamycin Phosphate RLD) — Sun Pharmaceutical Industries, Inc.. Clindamycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Clindamycin Phosphate RLD TARGET | Clindamycin Phosphate RLD | Sun Pharmaceutical Industries, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Clindamycin Phosphate RLD CI watch — RSS
- Clindamycin Phosphate RLD CI watch — Atom
- Clindamycin Phosphate RLD CI watch — JSON
- Clindamycin Phosphate RLD alone — RSS
Cite this brief
Drug Landscape (2026). Clindamycin Phosphate RLD — Competitive Intelligence Brief. https://druglandscape.com/ci/clindamycin-phosphate-rld. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing